Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...

For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise ...

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

The National Institute of Standards and Technology’s Artificial Intelligence Safety Institute is seeking information on the development of chemical and biology-focused artificial intelligence models.

Global Ecology and Biogeography, Vol. 27, No. 3/4 (March & April 2018), pp. 277-284 (8 pages) Motivation: The availability of user-friendly, high-resolution global environmental datasets is crucial ...

Glioblastoma (GBM), the most common malignant brain tumor, remains difficult to treat because cancer stem cells (CSCs) drive resistance and recurrence. Although the Bruton tyrosine kinase (BTK) ...

The disease-relevant mutation is engineered into bit.bio’s human ioWild Type TM cells using CRISPR/Cas9 gene editing. As disease model cells come from an identical human genetic background to ioWild ...